Get the Stockscreener App
188.94
1.89%
-3.63
After Hours:
189.50
0.56
+0.30%
Moderna Inc stock is traded at $188.94, with a volume of 15.40M.
It is down -1.89% in the last 24 hours and up +22.47% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$192.57
Open:
$186.61
24h Volume:
15.40M
Relative Volume:
0.92
Market Cap:
$75.43B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-23.19
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
-3.02%
1M Performance:
+22.47%
6M Performance:
+277.65%
1Y Performance:
+584.57%
1-Day Range:
$186.01
$201.00
1-Week Range:
$184.58
$208.90
52-Week Range:
$22.28
$208.90
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
188.94 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
506.74 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
734.81 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
936.00 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.89 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna stock after-hours at EUR 170.09: plus 0.70 percent versus the prior close - AD HOC NEWS
Moderna Stock Is Trending: What's Going On? - Benzinga
Top Healthcare Stocks To Watch TodayOctober 1st - MarketBeat
Moderna loses US government license defense in Northwestern patent case - reuters.com
Why Citi Is Sounding the Alarm on Moderna Stock - Barchart.com
Moderna Climbs 3% Despite Citigroup’s Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water - Yahoo Finance
Moderna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water - 247wallst.com
Moderna Stock Gets Sell Call As Oncology Hopes Face Valuation Test - Simply Wall Street
The Escalator: Moderna, Hatteras Venture Partners, PhRMA and more - Medical Marketing and Media
Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet - FinancialContent
Moderna adds COO role. Moderna stock falls 1.40 percent - AD HOC NEWS
Moderna, Cerebras, Jabil, HPE, Cal-Maine, Mattel, and More Stocks That Explain Today’s Market - Barron's
Moderna, Inc. Announces Management Changes - marketscreener.com
Why Moderna (MRNA) Shares Are Falling Today - Yahoo Finance
This Analyst Just Downgraded Moderna Stock. Here's Why. - Yahoo Finance
Citi Downgrades Moderna Stock, Warning $80 Billion Valuation Asks Too Much of Cancer Pipeline - Barron's
Moderna Stock Slumps as Citi Says It’s Time to Sell After 500% Rally This Year - Investopedia
Moderna Shares Reverse Weakness, Rise Over 3% After Key Trading Signal - Benzinga
Citi delivers major verdict after Moderna’s remarkable 703% run - thestreet.com
Prediction: Moderna Stock Will Soar 100% by 2030 - Yahoo Finance
Prediction: Moderna Stock Will Soar 100% by 2030 - The Motley Fool
What's Going On With Moderna Stock on Wednesday? - Benzinga
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now? - Zacks Investment Research
Moderna Tumbles as Citi Advises Selling Following 600% Rally - Bloomberg.com
Moderna (MRNA) Options Traders Turn Moderately Bearish Amid Pric - GuruFocus
Moderna (NASDAQ:MRNA) Shares Gap DownHere's Why - MarketBeat
Moderna and Fair Isaac: The Best and Worst S&P 500 Stocks for the Third Quarter - Barron's
Citi tells investors it’s time to sell Moderna after 600%-plus stock gains - MarketWatch
Moderna (MRNA) Shares Drop 6.88% Premarket After Citi Downgrade Citing Valuation Concerns - GuruFocus
Moderna Inc Stock (MRNA) Opened Down by 6.27% on Sep 30: Key Drivers Unveiled - TradingKey
Three biotech updates, including accusations of theft and and a new lobbying leader - statnews.com
Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat - Yahoo Finance
Target upgraded, Moderna downgraded: Wall Street's top analyst calls - Yahoo Finance
MRNA Stock Downgraded As Valuation Fears Eclipse Cancer Win - StocksToTrade
MRNA Stock Downgraded As Valuation Fears Clash With Trial Success - timothysykes.com
Moderna (MRNA) Shares Fall Premarket After Citi Downgrades to Se - GuruFocus
MRNA Stock Falls Premarket After Citi Downgrade: Analyst Says Valuation Looks Stretched Despite Cancer Vaccine Momentum - Yahoo Finance
Premarket movers: Micron; Boeing rises, Moderna slides - Yahoo Finance
Moderna Names Juan Andres as COO - marketscreener.com
Moderna stock slips as Citi cuts to Sell (MRNA:NASDAQ) - Seeking Alpha
Moderna: Citi says oncology optimism is priced in, cuts rating to sell - Yahoo! Finance Canada
Citi Downgrades Moderna Stock after 222% Rally, Calls Oncology Expectations “Unrealistic” - TipRanks
Moderna names Juan Andres chief operating officer - TradingView
Moderna names Juan Andres as chief operating officer - Investing.com
Moderna Adds Chief Operating Officer Role as Company Expands into Oncology - ACCESS Newswire
Moderna, Inc. (MRNA) Adds COO; Andres Returns, Collins Retires - TradingView
Citigroup Downgrades Moderna to Sell From Neutral, Adjusts Price Target to $80 From $60 - marketscreener.com
Moderna Sets Another Fresh 52-Week High: What's Happening? - Benzinga
Bayer Advances Patent Suit Over Moderna, Pfizer Covid Vaccines - Bloomberg Law News
Moderna And Merck: The Intismeran Readout That Was Worth $86 Billion (NASDAQ:MRNA) - Seeking Alpha
Precision Trading with Moderna Inc. (MRNA) Risk Zones - Stock Traders Daily
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moderna Inc Stock (MRNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hoge Stephen | President |
Sep 15 '26 |
Option Exercise |
12.21 |
76,452 |
933,479 |
1,602,310 |
| Hoge Stephen | President |
Sep 15 '26 |
Sale |
146.07 |
40,281 |
5,883,846 |
1,562,029 |
| Hoge Stephen | President |
Sep 14 '26 |
Sale |
144.13 |
40,294 |
5,807,574 |
1,525,858 |
3.09%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):